On Mar 6, during the press conference held by the Joint Prevention and Control Mechanism of the State Council, Mr. Cheng Jing, the academician of Chinese Academy of Engineering, the chair professor of School of Medicine in Tsinghua university,the founder of CapitalBio Technology, answered the media questions on 2019-nCov diagnosis regarding test sensitivity, convenience, current progress and up-coming arrangements. These issues are of high degree of concern by society and public at the moment.
Academician Cheng Jing says: So far there are 7 emergency projects got approved by NMPA in last 2 weeks and now they can be officially applied for clinical purpose. Among the 7 approved kits, the Respiratory Virus Nucleic Acid Detection Kit, which is based on Isothermal Nucleic Acid Amplification Microfluidic Chip technology, could detect 6 kinds of virus simutenously in a short period of time. It has three outstanding advantages over current Nuclear Acid detection kits:
- Simutenously detect various kinds of respiratory virus in short time.
- Faster detection speed than current kits, just takes 1.5 hours to finish the entire process.
- Brings great benefits to medical staff for differential diagnosis: quickly distinguish Covid-19 patients from those infected by other virus, or distringuish even more compilicated situation like co-infection or cross-infections.